Mesabi Trust (MSB) News
Follow Mesabi Trust (MSB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Mesoblast Limited (MSB) Wins FDA OK For New Ryoncil Potency Assay
Mesoblast received FDA approval to implement its T-cell Proliferation Inhibition BioAssay (TIBA) for release and stability monitoring of commercial Ryoncil batches, alongside existing potency assays under its Biologics L
REGULATION | Sep 24, 2026, 11:03 AM UTC
L
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the Unit
REGULATION | Sep 24, 2026, 11:03 AM UTC
L
Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil
Mesoblast Limited ASX:MSB
REGULATION | Sep 24, 2026, 01:32 AM UTC
L
MESABI TRUST Q2 2026: Revenue $2.33M, EPS $(0.0072) — 10-Q Summary
Mesabi Trust reported second-quarter fiscal 2026 results, delivering $2.33M of revenue for the three months ended July 31, 2026, and a net loss of $95K, or $(0.0072) per unit, as royalty income declined sharply versus th
EARNINGS | Sep 11, 2026, 08:43 PM UTC
L
MSB: Lower iron ore prices and no bonus royalties led to reduced income and distributions this quarter
Royalty income and net income declined sharply year-over-year due to lower iron ore prices and the absence of bonus royalty revenue, despite higher production and shipments. Distributions to unitholders were reduced, and
EARNINGS | Sep 11, 2026, 08:34 PM UTC
L
Jefferies cuts Mesoblast price target 3.3% to A$2.90
Jefferies cut its Mesoblast price target by 3.3% to A$2.90 per share.
EQUITY | Aug 27, 2026, 09:30 PM UTC
L
Piper Sandler raises Mesoblast price target to $39
Piper Sandler raised its Mesoblast price target to $39.00/share from $35.00.
EQUITY | Aug 27, 2026, 05:36 PM UTC
M
Mesoblast flags significant losses for foreseeable future
Mesoblast says it anticipates significant losses for the foreseeable future.
EQUITY | Aug 27, 2026, 01:32 AM UTC
M
Mesoblast reports substantial revenue growth to US$120M
Mesoblast reported substantial revenue growth to US$120M.
EQUITY | Aug 27, 2026, 12:37 AM UTC
L
MSB expects double-digit growth on $115M FY26 revenue
MSB projects $115M FY26 revenue, citing strong pipeline progress and expected double-digit growth next year.
EARNINGS | Aug 26, 2026, 11:54 PM UTC
M
MSB revenue jumps; net loss halves; clinical milestones met
MSB reports revenue up 600% to $120M and net loss halved, alongside key clinical milestones achieved.
EQUITY | Aug 26, 2026, 11:05 PM UTC
L
MSB: RYONCIL's $115M launch year revenue fuels late-stage pipeline and strengthens financial position
MSB: RYONCIL's $115M launch year revenue fuels late-stage pipeline and strengthens financial position
EQUITY | Aug 26, 2026, 11:01 PM UTC
M
MSB reports 599% revenue surge on Ryoncil US launch
MSB says revenues rose 599% to $120.3M with Ryoncil®’s US launch. Net loss fell 44% to $57.5M.
EQUITY | Aug 26, 2026, 10:35 PM UTC